<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl1">
 <label>Table 1</label>
 <caption>
  <p>Approved nucleos(t)ide-based antiviral and antineoplastic drugs with multi-target activity.</p>
 </caption>
 <alt-text id="alttext0045">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Name</th>
    <th>Type</th>
    <th>Approved antiviral drug (approval date)</th>
    <th>Approved antineoplastic drug (approval date)</th>
    <th>Active clinical-stage development
     <xref rid="tbl1fna" ref-type="table-fn">a</xref>
    </th>
    <th>Experimental development</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Acyclovir</td>
    <td align="left">Acyclic guanosine analogue</td>
    <td align="left">HSV, VZV (1982)</td>
    <td/>
    <td/>
    <td align="left">Breast cancer (
     <xref rid="bib90" ref-type="bibr">Shaimerdenova et al., 2017</xref>)
     <break/>EBV (
     <xref rid="bib72" ref-type="bibr">Pagano et al., 2018</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Azacitidine</td>
    <td align="left">Cytidine analogue</td>
    <td/>
    <td align="left">Myelodysplastic syndrome (2004)</td>
    <td/>
    <td align="left">AdV (
     <xref rid="bib3" ref-type="bibr">Alexeeva et al. (2001)</xref>; (
     <xref rid="bib4" ref-type="bibr">Alexeeva et al., 2015</xref>)
     <break/>HMPV (
     <xref rid="bib11" ref-type="bibr">Bösl et al., 2019</xref>)
     <break/>HIV-1 (
     <xref rid="bib20" ref-type="bibr">Dapp et al., 2009</xref>; 
     <xref rid="bib82" ref-type="bibr">Rawson et al., 2016a</xref>)
     <break/>HIV-1 – synergy in combination with resveratrol (
     <xref rid="bib83" ref-type="bibr">Rawson et al., 2016b</xref>)
     <break/>HIV-2 (
     <xref rid="bib9" ref-type="bibr">Beach et al., 2014</xref>)
     <break/>RVFV (
     <xref rid="bib41" ref-type="bibr">Ianevski et al., 2018</xref>)
     <break/>HTLV-1 (
     <xref rid="bib31" ref-type="bibr">Diamantopoulos et al., 2012</xref>)
     <break/>HSV-1, FLUAV (
     <xref rid="bib41" ref-type="bibr">Ianevski et al., 2018</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Brivudine</td>
    <td align="left">Thymidine analogue</td>
    <td align="left">HSV-1, VZV (2002)
     <xref rid="tbl1fnb" ref-type="table-fn">b</xref>
    </td>
    <td/>
    <td/>
    <td/>
   </tr>
   <tr>
    <td align="left">Clofarabine</td>
    <td align="left">Adenosine analogue</td>
    <td/>
    <td align="left">Acute lymphoblastic leukaemia (2004)</td>
    <td/>
    <td align="left">HIV-1 (
     <xref rid="bib19" ref-type="bibr">Daly et al., 2016</xref>)
     <break/>HIV-1, HIV-2 (
     <xref rid="bib9" ref-type="bibr">Beach et al., 2014</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Decitabine</td>
    <td align="left">Cytidine analogue</td>
    <td/>
    <td align="left">Myelodysplastic syndrome (2006)</td>
    <td/>
    <td align="left">HIV-1 (
     <xref rid="bib18" ref-type="bibr">Clouser et al., 2010</xref>)
     <break/>HIV-1 – synergy in combination with gemcitabine (
     <xref rid="bib18" ref-type="bibr">Clouser et al., 2010</xref>)
     <break/>HIV-1 – synergy in combination with resveratrol (Jonathan M.O. 
     <xref rid="bib83" ref-type="bibr">Rawson et al., 2016b</xref>)
     <break/>MuLV (
     <xref rid="bib17" ref-type="bibr">Clouser et al., 2012</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Famciclovir</td>
    <td align="left">Acyclic guanosine analogue</td>
    <td align="left">HSV, VZV (1994)</td>
    <td/>
    <td/>
    <td/>
   </tr>
   <tr>
    <td align="left">Galidesivir</td>
    <td align="left">Adenosine analogue</td>
    <td align="left">EBOV (n/a)</td>
    <td/>
    <td align="left">MARV (phase 1, NCT03800173)
     <break/>YFV (phase 1, NCT03891420)
    </td>
    <td align="left">ZIKV (
     <xref rid="bib46" ref-type="bibr">Julander et al., 2017</xref>) broad-spectrum antivirals (
     <xref rid="bib105" ref-type="bibr">Westover et al., 2018</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Ganciclovir</td>
    <td align="left">Acyclic guanosine analogue</td>
    <td align="left">HSV, VZV, CMV (1989)</td>
    <td/>
    <td/>
    <td align="left">EBV (
     <xref rid="bib72" ref-type="bibr">Pagano et al., 2018</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Gemcitabine</td>
    <td align="left">Cytidine analogue</td>
    <td/>
    <td align="left">Various carcinomas (1995): non-small cell lung cancer, pancreatic cancer, bladder cancer breast cancer ovarian cancer</td>
    <td/>
    <td align="left">HIV-1 (
     <xref rid="bib81" ref-type="bibr">Rawson et al. (2013)</xref>; 
     <xref rid="bib18" ref-type="bibr">Clouser et al. (2010)</xref>; (
     <xref rid="bib17" ref-type="bibr">Clouser et al., 2012</xref>)
     <break/>HIV-1 – synergy in combination with decitabine (
     <xref rid="bib18" ref-type="bibr">Clouser et al., 2010</xref>)
     <break/>MuLV (
     <xref rid="bib17" ref-type="bibr">Clouser et al., 2012</xref>)
     <break/>HIV-2 (
     <xref rid="bib9" ref-type="bibr">Beach et al., 2014</xref>)
     <break/>ZIKV (
     <xref rid="bib50" ref-type="bibr">Kuivanen et al., 2017</xref>)
     <break/>Enteroviruses including poliovirus (
     <xref rid="bib48" ref-type="bibr">Kang et al., 2015</xref>; 
     <xref rid="bib112" ref-type="bibr">Zhang et al., 2017</xref>)
     <break/>Enteroviruses – synergy with ribavirin (
     <xref rid="bib48" ref-type="bibr">Kang et al., 2015</xref>)
     <break/>Rhinoviruses (
     <xref rid="bib93" ref-type="bibr">Song et al., 2017</xref>)
     <break/>HCV (
     <xref rid="bib10" ref-type="bibr">Beran et al., 2012</xref>)
     <break/>Coronaviruses (
     <xref rid="bib32" ref-type="bibr">Dyall et al., 2014</xref>)
     <break/>SINV, HSV-1, FLUAV (
     <xref rid="bib30" ref-type="bibr">Denisova et al., 2012</xref>)
     <break/>Gram-positive bacteria (
     <xref rid="bib44" ref-type="bibr">Jordheim et al., 2012</xref>; 
     <xref rid="bib86" ref-type="bibr">Sandrini et al., 2007</xref>; 
     <xref rid="bib99" ref-type="bibr">Thomson and Lamont, 2019</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Lamivudine</td>
    <td align="left">L-Cytidine analogue</td>
    <td align="left">HIV (1999)
     <break/>HBV (1995)
    </td>
    <td/>
    <td/>
    <td/>
   </tr>
   <tr>
    <td align="left">Penciclovir</td>
    <td align="left">Acyclic guanosine analogue</td>
    <td align="left">HSV, VZV (1996)</td>
    <td/>
    <td/>
    <td/>
   </tr>
   <tr>
    <td align="left">Ribavirin</td>
    <td align="left">Nucleoside analogue</td>
    <td align="left">RSV, HCV (1985) viral haemorrhagic fevers</td>
    <td/>
    <td align="left">HBV (phase 3, (NCT03759782, in combination with tenofovir)</td>
    <td align="left">Enteroviruses (
     <xref rid="bib8" ref-type="bibr">Bauer et al., 2017</xref>)
     <break/>Influenza virus (
     <xref rid="bib75" ref-type="bibr">Pauly and Lauring, 2015</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Sofosbuvir</td>
    <td align="left">Uridine nucleotide analogue</td>
    <td align="left">HCV (2013)</td>
    <td/>
    <td align="left">HBV (phase 2, NCT03312023; I combination with ledipasvir)</td>
    <td align="left">DENV (
     <xref rid="bib108" ref-type="bibr">Xu et al., 2017</xref>)
     <break/>YFV (
     <xref rid="bib29" ref-type="bibr">De Freitas et al., 2019</xref>)
     <break/>ZIKV (
     <xref rid="bib65" ref-type="bibr">Mesci et al., 2018</xref>; 
     <xref rid="bib12" ref-type="bibr">Bullard-Feibelman et al., 2017</xref>)
     <break/>CHIKV (
     <xref rid="bib35" ref-type="bibr">Ferreira et al., 2019</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Telbivudine</td>
    <td align="left">L-Thymidine</td>
    <td align="left">HBV (2006)</td>
    <td/>
    <td/>
    <td align="left">Immunomodulatory, anti-inflammatory properties (
     <xref rid="bib102" ref-type="bibr">Van Linthout et al., 2018</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Tenofovir disoproxil</td>
    <td align="left">Acyclic adenosine nucleotide analogue</td>
    <td align="left">HIV (2001)
     <break/>HBV (2008)
    </td>
    <td/>
    <td/>
    <td/>
   </tr>
   <tr>
    <td align="left">Tenofovir alafenamide</td>
    <td align="left">Acyclic adenosine nucleotide analogue</td>
    <td align="left">HBV (2016)
     <break/>HIV (several combination, see 
     <xref rid="tbl2" ref-type="table">Table 2</xref>)
    </td>
    <td/>
    <td align="left">HBV (phase 2, NCT03434353, in combination with inarigivir)</td>
    <td/>
   </tr>
   <tr>
    <td align="left">Trifluridine</td>
    <td align="left">Thymidine analogue</td>
    <td align="left">HSV (1980)</td>
    <td align="left">Metastatic colorectal cancer (2015) in combination with tipiracil</td>
    <td/>
    <td align="left">Mycoplasma pneumonia (
     <xref rid="bib96" ref-type="bibr">Sun and Wang, 2013</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Valaciclovir</td>
    <td align="left">Acyclic guanosine analogue</td>
    <td align="left">HSV, VZV, CMV (1995)</td>
    <td/>
    <td/>
    <td/>
   </tr>
   <tr>
    <td align="left">Valganciclovir</td>
    <td align="left">Acyclic guanosine analogue</td>
    <td align="left">HSV, VZV, CMV (2001)</td>
    <td/>
    <td/>
    <td align="left">EBV (
     <xref rid="bib72" ref-type="bibr">Pagano et al., 2018</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">Vidarabine</td>
    <td align="left">Arabinosyl adenine analogue</td>
    <td align="left">HSV, VZV (1976)</td>
    <td/>
    <td/>
    <td/>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="tbl1fna">
   <label>a</label>
   <p id="ntpara0010">Clinical data from 
    <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="intref0010" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> (see 
    <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/" id="intref0015" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.clinicaltrials.gov/</ext-link>) in July 2019.
   </p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tbl1fnb">
   <label>b</label>
   <p id="ntpara0015">Approved by European Medicines Agency (EMA).</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
